Log in to search using one of your social media accounts:

 

Positive CHMP opinion for adalimumab biosimilar CYLTEZO
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 14, 2017 Category: Research Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2017 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira ®
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: (Source: World Pharma News)
Source: World Pharma News - September 4, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 29, 2017 Category: Drugs & Pharmacology Source Type: news

Adalimumab biosimilar CYLTEZO receives FDA approval
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 28, 2017 Category: Research Source Type: news

FDA Approves Second Humira Biosimilar, Cyltezo FDA Approves Second Humira Biosimilar, Cyltezo
Adalimumab-adbm Cyltezo, from Boehringer Ingelheim, is approved for multiple indications including treatment of adults with moderate-to-severe active rheumatoid arthritis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Second Humira Biosimilar Approved
(MedPage Today) -- FDA announces approval of Cyltezo (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 25, 2017 Category: American Health Source Type: news

Samsung, Biogen version of AbbVie's Humira approved in Europe
(Reuters) - Biogen Inc's version of AbbVie Inc's blockbuster arthritis drug Humira has been approved by European Union regulators, Biogen and joint venture partner Samsung Biologics said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - August 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Finger prick test allows patients taking autoimmune drug to avoid blood draws
(Wiley) A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2017 Category: International Medicine & Public Health Source Type: news

Boehringer Ingelheim initiates interchangeability trial of BI 695501 and Humira
Boehringer Ingelheim has initiated patient enrolment in an interchangeability clinical trial (VOLTAIRE-X) of its product candidate BI 695501 and the US-marketed formulation of 40mg/0.8mL Humira. (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

AbbVie to remain cautious on drug pricing, shares fall
(Reuters) - AbbVie Inc's said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on Humira, Imbruvica demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit beats on robust Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported quarterly earnings on Friday that edged past analysts' expectations, helped by robust demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's profit rises 19 percent on Humira demand
(Reuters) - U.S. drugmaker AbbVie Inc reported an 18.9 percent rise in quarterly profit on Friday on strong demand for its flagship rheumatoid arthritis drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Interchangeability study on BI 695501 vs Humira
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 26, 2017 Category: Research Source Type: news

CHMP Recommends Imraldi, a Biosimilar to Humira CHMP Recommends Imraldi, a Biosimilar to Humira
The CHMP has recommended Imraldi, a biosimilar to Humira.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

EU backs second biosimilar copy of Humira, world's top drug
FRANKFURT (Reuters) - European regulators have recommended approval of a second copy of AbbVie's rheumatoid arthritis drug Humira, the world's top-selling medicine, in a further boost for so-called biosimilars in the region. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD
This study found that infliximab and adalimumab present differing effects.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New Biosimilar for Adalimumab in Rheumatoid Arthritis New Biosimilar for Adalimumab in Rheumatoid Arthritis
A large multinational study compares the efficacy and safety of FKB327 biosimilar to adalimumab in active rheumatoid arthritis. But antidrug antibody levels raise questions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA ®
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid. (Source: World Pharma News)
Source: World Pharma News - June 15, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

biosimilar candidate shows clinical equivalence Humira
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 14, 2017 Category: Research Source Type: news

AbbVie shares dip after it loses round in Humira patent fight
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 16, 2017 Category: Pharmaceuticals Source Type: news

Adalimumab Effective in Children and Adolescents With Severe Psoriasis Adalimumab Effective in Children and Adolescents With Severe Psoriasis
Adalimumab offers benefits over methotrexate in children and adolescents with severe chronic plaque psoriasis, according to a phase 3 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news

JIA Uveitis Control Improved With Adalimumab + MTX JIA Uveitis Control Improved With Adalimumab + MTX
Adding adalimumab to MTX for treatment-resistant uveitis was associated with juvenile idiopathic arthritis improved disease control and enabled many patients to reduce or stop topical glucocorticoids.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

AbbVie profit beats on Humira demand; cheers Trump tax plan
(Reuters) - AbbVie Inc reported a bigger-than-expected quarterly profit, lifted by demand for its flagship drug, Humira, and called President Donald Trump's tax plan "encouraging". (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Clinical trial discovers a new way to prevent children with arthritis and eye disease losing their sight
This study demonstrates the benefit of adalimumab in children with uveitis. This is the first randomised trial of its kind worldwide and the results will have a major impact in children with uveitis all around the world."Finding the best way of caring for children with arthritis and uveitisProfessor Beresford from University of Liverpool and Alder Hey Children’s NHS Foundation Trust said: "This landmark trial has demonstrated the commitment and leadership of colleagues across the UK in working closely with patients and parents in tackling a key priority of finding the very best way of caring for children wi...
Source: Arthritis Research UK - April 26, 2017 Category: Rheumatology Source Type: news

What Causes Uveitis?
Discussion Inflammation of the middle layer of the eye, or uvea, is termed uveitis. Uveitis can be divided into anterior, intermediate or posterior uveitis by involving the anterior (iris and ciliary body), intermediate (vitreous) or posterior (choroid and usually retina) compartments. Panuveitis involves all 3 compartments. Duration can also be used to classify uveitis. Acute is 6 weeks and> 3 months is chronic persistent uveitis. Episodic periods of inactivity and reactivity that last more than 3 months are called recurrent uveitis. A third way to characterize uveitis is if it is granulomatous or not. Uveitis increase...
Source: PediatricEducation.org - April 3, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab) Prescribing Information
NORTH CHICAGO, Ill., March 30, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2017 Category: Drugs & Pharmacology Source Type: news

Fingernail Psoriasis Data Added to Humira Prescribing Info Fingernail Psoriasis Data Added to Humira Prescribing Info
The FDA has approved the addition of moderate to severe fingernail psoriasis data to the Humira prescribing information for those with moderate to severe chronic plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 30, 2017 Category: Dermatology Tags: Dermatology News Alert Source Type: news

U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
NORTH CHICAGO, Ill., March 30, 2017 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail ps... Biopharmaceuticals, FDA AbbVie, HUMIRA, adalimumab, Fingernail Psoriasis, Psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 30, 2017 Category: Pharmaceuticals Source Type: news

European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-s...
Source: Amgen News Release - March 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

AS: TNF Inhibitors Differ in Uveitis Risk (CME/CE)
(MedPage Today) -- Adalimumab and infliximab have lowest risk (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 18, 2017 Category: Geriatrics Source Type: news

New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira ® in Treatment of Moderate to Severe Plaque Psoriasis
Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA ® in the Treatment of Moderate to Severe Plaque Psoriasis (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 3, 2017 Category: Pharmaceuticals Source Type: news

Infliximab vs. Adalimumab in Crohn's Disease Infliximab vs. Adalimumab in Crohn's Disease
Do the anti-TNF agents infliximab and adalimumab have comparable response characteristics? Are concomitant immunomodulators necessary for optimal response?Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 28, 2017 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news

Report finds pharma companies limited January list price hikes
Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago. However, the median drug-price increase held steady compared to last year at 8.9% – far exceeding the U.S. inflation rate of 2%. Price increases held below 10% can still drive up total drug spending by hundreds of millions of dollars, according to the Wall Street Journal. AbbVie (NYSE:ABBV) raised the lis...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Healthcare Reform Pharma Pharmaceuticals Wall Street Beat AbbVie Allergan Inc. Johnson & Johnson Marathon Pharmaceuticals Merck Novo Nordisk Source Type: news

Remicade vs. Humira
Title: Remicade vs. HumiraCategory: MedicationsCreated: 2/27/2017 12:00:00 AMLast Editorial Review: 2/27/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 27, 2017 Category: Drugs & Pharmacology Source Type: news

Baricitinib Might Offer Oral Alternative to Adalimumab in RA Baricitinib Might Offer Oral Alternative to Adalimumab in RA
A phase 3 trial in patients with rheumatoid arthritis who did not respond to methotrexate showed that the addition of baricitinib produced significant clinical improvements.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New non-steroid treatment for uveitis
Treatment TermsUveitis CategoriesAdvanced treatmentsClinical trials Additional SEO Keywords uveitis, Humira SEO Meta Description A clinical trial at Duke for a drug approved by the FDA to treat uveitis helped Shirley Mims see clearly again. Author Karen Doss Bowman Overview Shirley Mims thought she would go blind when she was first diagnosed with uveitis. A clinical trial at Duke for a drug now approved by the FDA to treat uveitis helped her see clearly again. Hero Imagestory_181716_jaffe047.jpg Preview Image Content Blocks Header Suddenly seeing spots ContentShirley Mims was driving home from her job as an ...
Source: dukehealth.org: Duke Health News - February 20, 2017 Category: Consumer Health News Authors: dg62 at duke.edu Source Type: news

Baricitinib Scores High in Phase III (CME/CE)
(MedPage Today) -- Superior to adalimumab for clinical and functional outcomes (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 15, 2017 Category: Geriatrics Source Type: news

Adalimumab Effective in Crohn's Disease With Strictures Adalimumab Effective in Crohn's Disease With Strictures
The TNF inhibitor works well for patients with Crohn's disease accompanied by symptomatic strictures; disease control was well maintained in those who respond through nearly 4 years of follow-up.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Amgen Gets EMA Ok for Humira Biosims
The European Medicines Agency (EMA) recommended the approval of two Amgen biosimilars for AbbVie ’s blockbuster Humira, for treatment of inflammatory diseases. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 28, 2017 Category: Pharmaceuticals Source Type: news

Arthritis Drugs Get Nod From EMA's CHMP Arthritis Drugs Get Nod From EMA's CHMP
Tofacitinib citrate (Xeljanz), two adalimumab (Humira) biosimilars, and one methotrexate hybrid get thumbs up from EMA committee.International Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 27, 2017 Category: Dermatology Tags: Rheumatology News Alert Source Type: news

Psoriasis and Arthritis Drugs Get Nod From EMA's CHMP Psoriasis and Arthritis Drugs Get Nod From EMA's CHMP
Tofacitinib citrate (Xeljanz), two adalimumab (Humira) biosimilars, and one methotrexate hybrid get thumbs up from EMA committee.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 27, 2017 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Adalimumab Biosimilar Candidate Recommended for EMA Approval THOUSAND OAKS, Calif., Jan. 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 501 (biosimilar adalimumab), recommending approval for all available indications. ABP 501 has been recommended for approval for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis (AS)...
Source: Amgen News Release - January 27, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Boehringer Ingelheim biosimilar candidate to Humira ® accepted for EMA and FDA regulatory review
Boehringer Ingelheim announced that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA). (Source: World Pharma News)
Source: World Pharma News - January 19, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Guselkumab Beats Adalimumab for Moderate to Severe Psoriasis Guselkumab Beats Adalimumab for Moderate to Severe Psoriasis
Guselkumab is effective for treating patients with moderate to severe psoriasis, according to results from Janssen's VOYAGE 1 and VOYAGE 2 trials.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 17, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Boehringer Ingelheim biosimilar candidate to Humira < sup > ® < /sup > accepted for EMA and FDA regulatory review
Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 17, 2017 Category: Research Source Type: news

Pfizer reports positive top-line data from REFLECTIONS B538-02 study of PF-06410293
Pfizer has reported positive top-line data from its REFLECTIONS B538-02 study of PF-06410293 compared with Humira to treat moderate-to-severe rheumatoid arthritis (RA). (Source: Drug Development Technology)
Source: Drug Development Technology - January 9, 2017 Category: Pharmaceuticals Source Type: news

Momenta's Humira biosimilar succeeds in key psoriasis study
(Reuters) - U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2016 Category: Consumer Health News Tags: healthNews Source Type: news